All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live
The Signal
This briefing reviews four investment pitches—MGM Resorts, Talon Energy, Actis Oncology, and Geonet—presented at a private best-ideas event. While MGM led in consensus rankings due to a live catalyst, all four pitches hinge on contested valuations and speculative future catalysts rather than established current fair market value. The central tension pits predictable, liquidity-rich assets against high-volatility, binary-outcome technological bets.
The Case
- MGM Resorts is currently defined by a bid floor after Barry Diller accumulated 26% of the company and made a $48 offer, creating a takeover-catalyst story atop potential but unproven long-term upside from Osaka and Dubai casino licenses.
- Talon Energy is pitched as an undervalued power bottleneck play holding 2 GW of nuclear and 6 GW of gas assets, with the thesis relying on the PJM grid demand forecast of 106 gigawatts of new power needs over the next decade.
- Actis Oncology promotes a radiopharmaceutical platform with early clinical readouts expected in 2027 and a 2027 Nectin 4 data catalyst early next year, though its $10B valuation target remains highly speculative and depends on binary trial success.
- Geonet is a decentralized geolocation network that claims 2-centimeter precision and uses 80% of its network revenue to buy its own tokens on the open market, creating a dividend-like mechanism that remains unproven at scale and legally untested.
- The panel’s final vote ranked MGM and Talon as the two most investable, liquid assets, while relegating Actis and Geonet to high-risk 'lottery ticket' status due to their scientific and binary nature.
- Kyle Samani, the Geonet presenter, explicitly clarified he owns the token but holds no company equity, a structure that flags potential incentive misalignment for investors comparing the asset class to traditional stock.
The 1 Minute Signal Take
The event succeeds as a market orientation for identifying high-conviction thematic speculation, but the provided valuation targets (e.g., $150 per share for MGM or $200 for Actis) are promotional pitch estimates rather than grounded, risk-adjusted projections. Investors should focus on the bid-floor logic for MGM and the power-demand mechanics for Talon, while treating the Actis and Geonet claims as early-stage experiments with significant binary downside. Watch this video if you want to observe how professional managers frame high-stakes, asymmetric risk for an audience, but skip it if you are looking for rigorous, independently audited valuation analysis.
Time saved: